NRDI Fund Programme

Press release

NRDI Fund Programme

Epavir is the only clinically proven oral antiviral natural health product that contains natural active ingredients.  It is a dominant player on the Hungarian market, it has been among the top 5 products against Herpes Virus for decades in Hungary. 

Sinnex’s project  “Development of new oral products containing natural active ingredients for the prevention of Influenza and COVID Viruses” examined the extension of indication of its product Epavir soft capsule – which are on the market for several years – for the prevention and therapy of influenza and COVID-19 viruses. The studies have shown that the product has potential for therapeutic use against Alzheimer’s disease. In the framework of the project, in vitro and in vivo studies were performed, and potential areas of use were explored. The successful research was based on decades of experience in drug discovery and development of the employees of Sinnex.

Besides vaccines, there is a growing potential for oral solutions that prevent or treat milder symptoms of Herpes Virus.  

The latest medical findings show that the Herpes virus (HSV1) plays a significant role in the development and progression of Alzheimer’s disease. One of the main challenges for the near future is the development of a product in this field, in which Epavir could play a major role (there is currently no drug on the world market for Alzheimer’s disease, so its market potential is huge). 

The product that will be developed could offer an effective solution in these areas, for prevention and for patients in the early stages of the disease. 

The project under the project identificatory: 2020-1.1.1-KKV-START-2021-00518, was implemented with the support of the Ministry of Innovation and Technology from the National Research, Development and Innovation Fund, funded by the KKV-START grant programme.

NKFI Alapból megvalósuló program